• Home
  •  / Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical

OverviewSuggest Edit

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. It is creating an improved model for successful rare disease drug development that increases efficiency and effectiveness by changing the way the process is organized and conducted. The Company believes that it can deliver significant value to its patients by building a diverse and high quality pipeline of rare disease therapeutics and efficiently transforming good science into great medicine. 

TypePublic
Founded2010
HQNovato, CA, USMap
Websiteultragenyx.com
Employee Ratings4.3More
Overall CultureA+More
View Jobs (108)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)740(+22%)
Job Openings108
Revenue (FY, 2020)$271 M(+162%)
Share Price (Sept 2021)$95.2(-5%)
Cybersecurity ratingDMore

Key People/Management at Ultragenyx Pharmaceutical

Daniel G. Welch

Daniel G. Welch

Chairman
Emil D. Kakkis

Emil D. Kakkis

Chief Medical Officer and Executive Vice President
Camille Bedrosian

Camille Bedrosian

Chief Medical Officer and Executive Vice President
Erik Harris

Erik Harris

Chief Commercial Officer and Executive Vice President
Dennis Huang

Dennis Huang

Chief Commercial Officer and Executive Vice President
Mardi Dier

Mardi Dier

Chief Medical Officer and Executive Vice President
Show more

Ultragenyx Pharmaceutical Office Locations

Ultragenyx Pharmaceutical has an office in Novato
Novato, CA, US (HQ)
60 Leveroni Ct
Show all (1)

Ultragenyx Pharmaceutical Financials and Metrics

Ultragenyx Pharmaceutical Revenue

Ultragenyx Pharmaceutical's revenue was reported to be $271.03 m in FY, 2020
USD

Revenue (Q1, 2021)

99.4m

Net income (Q1, 2021)

(136.1m)

EBIT (Q1, 2021)

(106.6m)

Market capitalization (14-Sept-2021)

6.4b

Closing stock price (14-Sept-2021)

95.2

Cash (31-Mar-2021)

383.8m
Ultragenyx Pharmaceutical's current market capitalization is $6.4 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

133.0k2.6m51.5m103.7m271.0m

Cost of goods sold

1.0k1.1m

Gross profit

2.6m50.3m

Gross profit Margin, %

100%98%
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

93.0k149.0k17.0k111.0k198.0k10.7m12.8m11.8m18.2m24.1m25.8m36.3m61.7m81.5m99.4m

Cost of goods sold

225.0k141.0k273.0k452.0k766.0k

Gross profit

10.5m12.7m11.5m17.7m23.4m

Gross profit Margin, %

98%99%98%98%97%
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

24.3m93.6m161.1m100.5m113.4m433.6m713.5m

Accounts Receivable

5.2m12.7m32.8m23.1m

Prepaid Expenses

28.7m42.9m51.4m57.6m

Inventories

5.9m13.1m20.1m757.0k7.1m11.5m13.0m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

55.4m17.5m53.4m178.0m52.4m166.7m70.8m55.1m142.3m159.5m90.8m60.4m226.7m110.9m83.0m269.7m131.3m122.6m298.2m335.6m197.5m383.8m

Accounts Receivable

3.7m17.4m9.2m15.6m20.9m23.1m29.3m14.9m27.8m25.0m

Prepaid Expenses

4.2m4.9m5.5m6.9m9.4m12.3m17.1m17.8m18.9m19.2m19.7m19.4m34.0m36.8m49.7m45.0m46.6m49.2m64.8m58.2m64.3m68.0m

Inventories

2.1m3.3m5.6m10.9m13.6m14.1m11.4m11.1m14.5m12.5m
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(59.8m)(145.6m)(245.9m)(302.1m)(197.6m)(402.7m)(186.6m)

Depreciation and Amortization

684.0k1.4m3.4m5.8m19.5m8.5m12.3m

Inventories

(4.1m)(7.1m)(7.1m)(5.3m)(4.5m)(1.3m)

Accounts Payable

3.2m(2.0m)2.5m3.5m3.4m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(13.6m)(27.2m)(43.1m)(21.4m)(51.2m)(90.4m)(52.8m)(109.7m)(174.6m)(68.3m)(141.2m)(220.4m)30.3m(22.5m)(109.8m)(96.8m)(195.9m)(308.9m)(119.0m)(93.7m)(162.6m)(136.1m)

Depreciation and Amortization

117.0k278.0k472.0k201.0k463.0k904.0k544.0k1.2m2.3m1.2m2.2m3.3m6.2m12.2m16.6m2.1m4.2m6.4m2.9m6.0m9.1m3.4m

Inventories

(3.6m)(6.0m)(6.6m)149.0k521.0k(2.6m)474.0k

Accounts Payable

2.1m2.0m2.7m437.0k4.8m(544.0k)2.6m2.8m3.8m3.0m6.4m3.9m(1.3m)1.4m(593.0k)(151.0k)(3.6m)266.0k
show all
USDQ1, 2014

Financial Leverage

1 x
Show all financial metrics

Ultragenyx Pharmaceutical Cybersecurity Score

Cybersecurity ratingPremium dataset

D

68/100

Learn more about our premium products
SecurityScorecard logo

Ultragenyx Pharmaceutical Online and Social Media Presence

Ultragenyx Pharmaceutical's Trends

Embed Graph

Ultragenyx Pharmaceutical Company Culture

  • Overall Culture

    A+

    83/100

  • CEO Rating

    A+

    98/100

  • Compensation

    B

    77/100

  • Diversity

    B

    72/100

Learn more on Comparably

Ultragenyx Pharmaceutical News and Updates

January 15, 2020

Thinking about buying stock in Bank of America, Nio, Ultragenyx Pharmaceutical, Tilray, or Walmart?

NEW YORK, Jan. 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BAC, NIO, RARE, TLRY, and WMT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
November 19, 2019

Why Ultragenyx Pharmaceutical Stock Has Dropped 40% In The Last Quarter

Ultragenyx Pharmaceuticals (NASDAQ: RARE), a biopharmaceutical company focused on serious rare and ultra-rare genetic diseases, has seen its stock price decline by close to 40% over the last 3 months. The decline could be due to the fact that the company posted wider than expected losses...
May 07, 2018

Ultragenyx Pharmaceutical's (RARE) CEO Emil Kakkis on Q1 2018 Results - Earnings Call Transcript

Ultragenyx Pharmaceutical Blogs

September 07, 2021

Ultragenyx to Present at Morgan Stanley Healthcare Conference

Ultragenyx to Present at Morgan Stanley Healthcare Conference Content Import Tue, 09/07/2021 - 16:30 Ultragenyx to Present at Morgan Stanley Healthcare Conference Sep 07, 2021 This release is a backfill from a News Wire General Releases …
September 01, 2021

Ultragenyx to Participate in Panel at Citi’s 16th Annual BioPharma Healthcare Conference

Ultragenyx to Participate in Panel at Citi’s 16th Annual BioPharma Healthcare Conference Content Import Wed, 09/01/2021 - 16:30 Ultragenyx to Participate in Panel at Citi’s 16th Annual BioPharma Healthcare Conference Sep 1, 2021 This release is a backfill fro…
August 02, 2021

Ultragenyx Reports Second Quarter 2021 Financial Results and Corporate Update

Second quarter 2021 total revenue of $87.0 million including Crysvita 1 revenue to Ultragenyx of $44.7 million 2021 Crysvita revenue in Ultragenyx territories 1 guidance of $180 million to $190 million reaffirmed Strong Dojolvi launch continues with approximately 220 patients on reimbursed
July 27, 2021

Ultragenyx to Host Conference Call for Second Quarter 2021 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for Second Quarter 2021 Financial Results and Corporate Update Content Import Tue, 07/27/2021 - 17:00 Ultragenyx to Host Conference Call for Second Quarter 2021 Financial Results and Corporate Update Jul 27, 2021 This releas…
May 18, 2021

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Content Import Tue, 05/18/2021 - 16:05 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 18, 2021 This release is a backfill from a News Wire …
May 10, 2021

Ultragenyx to Present at Bank of America Securities Healthcare Conference

Ultragenyx to Present at Bank of America Securities Healthcare Conference Content Import Mon, 05/10/2021 - 16:01 Ultragenyx to Present at Bank of America Securities Healthcare Conference May 10, 2021 This release is a backfill from a News Wire …
Show more

 Ultragenyx Pharmaceutical Frequently Asked Questions

  • When was Ultragenyx Pharmaceutical founded?

    Ultragenyx Pharmaceutical was founded in 2010.

  • Who are Ultragenyx Pharmaceutical key executives?

    Ultragenyx Pharmaceutical's key executives are Daniel G. Welch, Emil D. Kakkis and Camille Bedrosian.

  • How many employees does Ultragenyx Pharmaceutical have?

    Ultragenyx Pharmaceutical has 740 employees.

  • What is Ultragenyx Pharmaceutical revenue?

    Latest Ultragenyx Pharmaceutical annual revenue is $271 m.

  • What is Ultragenyx Pharmaceutical revenue per employee?

    Latest Ultragenyx Pharmaceutical revenue per employee is $366.3 k.

  • Who are Ultragenyx Pharmaceutical competitors?

    Competitors of Ultragenyx Pharmaceutical include Ionis Pharmaceuticals, Modis Therapeutics and Arrow Pharmaceuticals.

  • Where is Ultragenyx Pharmaceutical headquarters?

    Ultragenyx Pharmaceutical headquarters is located at 60 Leveroni Ct, Novato.

  • Where are Ultragenyx Pharmaceutical offices?

    Ultragenyx Pharmaceutical has an office in Novato.

  • How many offices does Ultragenyx Pharmaceutical have?

    Ultragenyx Pharmaceutical has 1 office.